stockportfolio.pro
First Tracks Biotherapeutics, Inc. (TRAX)
Healthcare · Biotechnology · NasdaqGS
First Tracks Biotherapeutics, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | — | — |
| Net income | $-106.15M | $-163.71M |
| Net margin | — | — |
Source: First Tracks Biotherapeutics, Inc. SEC filings (10-K).
Explore 2 years of First Tracks Biotherapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TRAX in your portfolio →
First Tracks Biotherapeutics, Inc. financial history by metric
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
First Tracks Biotherapeutics, Inc. — frequently asked questions
What is First Tracks Biotherapeutics, Inc.'s revenue?
First Tracks Biotherapeutics, Inc. (TRAX) reported revenue of $0 for fiscal year 2024, according to its SEC filings.
Is First Tracks Biotherapeutics, Inc. profitable?
No — TRAX reported a net loss of $-163.71M in fiscal 2024.
What is TRAX's P/E ratio?
First Tracks Biotherapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does First Tracks Biotherapeutics, Inc. have?
As of fiscal year 2024, TRAX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is First Tracks Biotherapeutics, Inc.'s market cap?
First Tracks Biotherapeutics, Inc. (TRAX) has a market capitalization of about $600.50M, based on the latest data in our nightly-refreshed cache.
When does First Tracks Biotherapeutics, Inc.'s fiscal year end?
TRAX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2024-12-31.
Where does this data come from?
All figures are computed from First Tracks Biotherapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.